FindTrial
Sign In

A retrospective study on the role and mechanism of Epstein-Barr virus protein BRRF2 in inhibiting innate immunity through exosomes

A retrospective study on the role and mechanism of Epstein-Barr virus protein BRRF2 in inhibiting innate immunity through exosomes

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600129636
Enrollment
Unknown
Registered
2026-08-07
Start date
2026-08-07
Completion date
Unknown
Last updated
2026-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nasopharyngeal carcinoma

Interventions

Nasopharyngeal carcinoma observation group:None

Sponsors

Sun Yat-sen University Cancer Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Paraffin-embedded tissue sections of nasopharyngeal carcinoma, and the serum of EBV-positive tumor patients who received immunotherapy

Exclusion criteria

Exclusion criteria: Incomplete medical records and insufficient sample size

Design outcomes

Primary

MeasureTime frame
The expression of BRRF2 in tissues and serum exosomes;—

Countries

China

Contacts

Public ContactQian Zhong

Sun Yat-sen University Cancer Center

zhongqian@sysucc.org.cn+86 20 87342662

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Aug 25, 2026